Comparison
While FOXO4-DRI acts as a senolytic in preclinical models by promoting apoptosis of senescent cells, improving tissue function and healthspan measures in aged animals38, Setmelanotide is approved for chronic weight management in patients with POMC, PCSK1, LEPR deficiencies and Bardet–Biedl syndrome by reducing hunger and promoting weight loss92.
While FOXO4-DRI works as a D-retro-inverso peptide derived from a FOXO4 region that competes with endogenous FOXO4 for binding to p53, thereby releasing p53 to trigger apoptosis selectively in senescent cells38, Setmelanotide is a potent synthetic melanocortin-4 receptor (MC4R) agonist derived from a POMC/α-MSH–related sequence that restores downstream MC4R signaling in genetic obesity syndromes3192100.
FOXO4-DRI is amino acids long, whereas Setmelanotide is the same length as it has a length of amino acids. FOXO4-DRI is made up of a sequence of sequence data not available in the current dataset. Setmelanotide is made up of a sequence of sequence data not available in the current dataset.
FOXO4-DRI
FOXO4
Setmelanotide
POMC
No related articles are linked to these peptides yet.